VIDEO CORNER: Treating Sleep Disorders…
Current Rating 4.5

For the seventy million people who suffer from sleep
disorders, getting treatment is nothing to yawn about!
http://www.evtv1.com/player.aspx?itemnum=9806

Do You Suffer from One of the Top 10 Most Embarrassing Ailments? Join the Club…

We all have health concerns from time to time that are a
little bit, um, shall we say personal? Well, guess what?
You’re not alone. In fact AOL has been good enough to put
together a list of the Top Searched Embarrassing Health
Concerns on AOL Search. And the winners (or losers) are:

1. Herpes

2. Irritable Bowel Syndrome (IBS)

3. Yeast Infection

4. Psoriasis

5. Urinary Tract Infection

6. Genital Warts

7. Hemorrhoids

8. Impotence

9. Hyperhidrosis

10. Incontinence
Continued below…
APPLE CIDER VINEGAR PILLS

Normal Price: $9.99
DEAL PRICE: $2.99 per bottle

The #1 ALL NATURAL Diet Product For The Last 50 Years
WILL Help YOU Lose Weight….

The best-selling and most proven All Natural diet aid
available. For the last 50 years hundreds of thousands
of people have successfully lost weight with Apple Cider
Vinegar….

Now you can get this Amazing supplement in an easy and
convenient tablet form. No more bad tasting liquids. And
it’s even more concentrated in the tablet form. Plus, it
is guaranteed to work for you. If you don’t lose the weight
you want with Amazing Apple Cider Vinegar just return it
for a refund. It’s JUST $2.99 for 60 Tablets. Visit:
http://pd.gophercentral.com/r/120/a/100119/l/ti4p52
FDA tests ‘personalized medicine’

WASHINGTON, — Medco Health Solutions is working with the
U.S. Food and Drug Administration to determine how a pati-
ent’s genes determine reactions to medicine. A pharmacy
benefits manager, Medco, will provide information for two
years on pharmacogenomics, The Wall Street Journal reported
Tuesday. Much of the information is available in Medco pat-
ient databases. The goal of the project is to test the use-
fulness of “personalized medicine.” “We’re all about making
this field happen as fast as it appropriately should hap-
pen,” Dr. Robert Epstein, Medco’s chief medical officer,
told the Journal. More than 20 tests are now available to
determine whether a patient is compatible with a certain
medication, Epstein said. The FDA will not receive infor-
mation from the Medco database that could be used to ident-
ify a specific patient, a company spokeswoman said.

Hepatitis B ‘nanovaccine’ Is Developed…

ANN ARBOR, Mich., — U.S. medical scientists say a new
“nanovaccine” for hepatitis B that shows promise for use in
the developing world has moved closer to human trials. Uni-
versity of Michigan researchers said the new nanoemulsion
eliminates three major problems associated with current vac-
cines — the need for refrigeration, difficulty in maintain-
ing needle and syringe sterility and the need for people to
return for the three-shot regimen. Although there are three
effective vaccines available, hepatitis B infects 400 -
million people worldwide, many of them children in Africa,
Asia and South America. But researchers at the University
of Michigan’s Nanotechnology Institute for Medicine and
Biological Sciences at the University of Michigan say their
new, needle-free method avoids all three drawbacks and ani-
mal tests indicate it provides non-toxic and strong, sus-
tained immune responses. “Our results indicate needle-free
nasal immunization, using a combination of nanoemulsion and
hepatitis B antigen, could be a safe and effective hepatitis
B vaccine, and also provide an alternative booster method
for existing vaccines,” said Dr. James Baker Jr., the
study’s senior author. Baker said researchers hope the first
human trial can begin within a year. The study is reported
in the online journal PLoS One.

                               *
 
 
Origin Of Brain Tumors In Children Found…
MUNICH, Germany, — German scientists say they’ve found the
developmental process of medulloblastoma — one of the most
malignant brain tumors among children and teenagers. In two
studies working with international scientific teams, Dr. -
Ulrich Schuller of Germany’s Ludwig Maximilian University
discovered the molecular mechanisms that lead to the dev-
elopment of such cerebellar tumors. The researchers trigg-
ered genetic changes in cell populations in the brains of
mice to provoke the growth of tumors. They found medullo-
blastomas arose from only one type of cell — granule cells
– and only if those cells were fully committed. “Medullo-
blastomas are presently treated with non-specific methods,”
said Schuller. “Our results could contribute to the develop-
ment of targeted therapies, and thus improve the treatment
of cerebellar tumors in children.” The research is reported
in the journal Cancer Cell.

Graduate Student Finds, Names Bacterium…

RIVERSIDE, Calif., — A U.S. graduate student in entomology
has made the dream of many scientists a reality in her own
life by finding and naming a new bacterium. University of
California-Riverside student Allison Hansen discovered and
named the bacterial pathogen that could be responsible for
psyllid yellows — a disease that infects and kills tomato
and potato plants. Hansen discovered the bacterium during
research on the symbionts of the tomato psyllid. A symbiont
is an organism that has an intimate relationship with ano-
ther organism of a different species. She named the pathogen
“Candidatus Liberibacter psyllaurous.” Liberibacter, she
said, is the genus in which the bacterium is nested; psyl-
laurous means psyllid yellows in Latin. “Allison has a spec-
ial gift of looking at questions from new perspectives and
recognizing relationships that others have either overlooked
or missed all together,” said Professor Timothy Paine,
Hansen’s adviser. “This ability has enabled her to make a
couple of key breakthroughs as a graduate student that have
stumped other scientists for decades.” Hansen’s discovery is
reported in a paper published in the online edition of the
journal Applied and Environmental Microbiology.

Focused Radiation May Control Some Cancers…

CHICAGO, — U.S. medical scientists say they’ve discovered
precisely targeted radiation therapy can eradicate all
evidence of cancer in some patients. Researchers from the
University of Chicago Medical Center said their ongoing
clinical trial found targeted radiation therapy completely
controlled all signs of cancer in 21 percent of the trial’s
patients who had five or fewer sites of metastatic disease.
“This was proof of principle in patients who had failed the
standard therapies and had few, if any, remaining options,”
said the study’s senior author, Dr. Ralph Weichselbaum, a
professor of radiation and cellular oncology. “We had en-
couraging results, including several long-term survivors,
in patients with stage-IV cancers that had spread to distant
sites.” In 1994, Weichselbaum and colleague Samuel Hellman
proposed there was an intermediate state between cancer that
had not spread at all and cancer that had spread exten-
sively. They named that state “oligometastases,” meaning
cancer that had spread to a few distant sites. The research-
ers said the new technique could also be applied after chem-
otherapy, in cases in which the drugs had eliminated most
the smaller cancer, leaving only a few larger tumors behind.
The trial’s latest results are reported in the journal Clin-
ical Cancer Research,
Health Tips and Info From EVTV1.com:
http://www.evtv1.com/Health.aspx